Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 06, 2026, titled "Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)".
Filed with NSE · ISIN INE935A01035 · · 3 pages · English
Summary by 6ix
Glenmark Pharmaceuticals Limited has announced the launch of Adapalene Gel USP in new pump packs through its subsidiary, Glenmark Therapeutics Inc., USA. This product is an over-the-counter treatment comparable to Differin Gel, aimed at enhancing consumer experience with convenient dispensing options. The launch reflects Glenmark's commitment to providing high-quality and affordable healthcare solutions in the dermatology sector.
6ix wrote this summary in English from the company’s filing.
Sub: Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC) Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch1 of Adapalene Gel USP, 0.1% (OTC) in new pump packs. Glenmark’s Adapalene Gel USP, 0.1% can be compared to the active ingredient of Differin®2 Gel, 0.1%. According to Nielsen® syndicated data for the latest 52-week period ending Sep
Earlier from Glenmark Pharmaceuticals
- Glenmark Pharmaceuticals Limited Press Release Sep 23 2026
- Glenmark Pharmaceuticals and South Piedmont Community College Launch Aseptic Training Facility in Monroe, N.C.
- Glenmark Pharmaceuticals Limited Press Release Aug 21 2026
- Glenmark Pharmaceuticals Limited Press Release Aug 20 2026